Introduction {#s1}
============

Aging is the leading risk factor for the development Parkinson\'s disease (PD), a most prevalent central nervous system (CNS) movement disorder characterized by the progressive and selective degeneration of midbrain dopaminergic neurons (mDA) of the substantia nigra pars compacta (SNpc) and their terminals in the striatum, the presence of intracellular aggregated inclusions containing α-synuclein (α-Syn), called Lewy bodies (LB), and an abnormal activation of the astroglial cell compartment (Hornykiewicz, [@B93]; Di Monte and Langston, [@B49]; Langston et al., [@B116], [@B115]; Table [1](#T1){ref-type="table"}).

###### 

Parkinson\'s disease: from hallmarks to therapy.

  **Hallmarks**                                                                                                                                                                                                                                                                                                                  **Genetic factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **Environmental factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **Protective factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Therapy**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Selective mDA neurodegeneration** in the SNpc with concurrent loss of mDA neuronal afferents to striatum and putamenα**-SYN aggregation** (Lewy bodies and Lewy neurites formation) indicative of ongoing degeneration**Astro and microgliosis** (astrocyte hypertrophy, M1-microglial morphological and functional shift)   **PARK Genes** (α-SYN/PARK1, LRRK2/PARK8[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}, PRKN/PARK2[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}, VPS35/PARK17[§](#TN1){ref-type="table-fn"}, UCH-L1/PARK5, GBA[§](#TN1){ref-type="table-fn"}**MAPTau**[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}**Dopaminergic related genes (**DA-receptors, DA-transporter, TH, COMT, MAO)**GSK-3**β[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}**Xenobiotic Metabolism/Detox-related genes** (P450IID1, CYP1A1, NAT1, HMOX1[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}, GST, NQO2)**APOENeurotrophic genes** (NURR1[§](#TN1){ref-type="table-fn"}, NGF, BDNF)**Inflammatory related genes** (iNOS, TNF-α, IL-1β, IL-6, ER-β)[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}   **Aging**[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}**Rural living** herbicides and pesticides exposure (paraquat, rotenone, organochlorines, carbamates)[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}, metal exposure[°](#TN2){ref-type="table-fn"}**Head injuriesEstrogen deficiency** (women)[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}**Infectious diseases** during childhood[§](#TN1){ref-type="table-fn"}[°](#TN2){ref-type="table-fn"}**Maternal factors/ early-life events** (virus, drugs, endotoxins, hormonal deficits)[°](#TN2){ref-type="table-fn"}**Drug-induced parkinsonism** (drug abuse, neuroleptics, calcium-channel blockers)[°](#TN2){ref-type="table-fn"}**miRNAs** (miR-155, miR-7116-5p)[°](#TN2){ref-type="table-fn"}   **Chronic use of NSAIDS** (reduces PD risk)[§](#TN1){ref-type="table-fn"}[^\*^](#TN3){ref-type="table-fn"}; [^\*\*^](#TN4){ref-type="table-fn"}**Estrogen replacement therapy** (post-menopausal women, OVX animals)[^\*^](#TN3){ref-type="table-fn"}**Dietary factors/life style** (tea, polyphenols, wine components, curcumin, coffee, tobacco)[^\*^](#TN3){ref-type="table-fn"}**Environment (**Exercise, social interactions)[§](#TN1){ref-type="table-fn"}[^\*\*^](#TN4){ref-type="table-fn"}**miRNA** (miR-7)[^\*^](#TN3){ref-type="table-fn"}   **Symptomatic**: L-DOPA or DAergic agents administration (relieve motor symptoms, do not prevent disease progression)**Neuroprotective/symptomatic** (selegiline, rasagiline)**Cell based therapies** (re-introducing DA-producing cells, embryonic, NSCs, treated iPSCs, to replenish DA stores and alleviate/cure PD**Combined therapies (**anti-oxidants, anti-inflammatories, GSK-3β-inhibitors, protective factors to boost endogenous neurogenesis and mDA neuro-restoration)

*Wnt/β-CAT dysregulation in the reported conditions*.

*Activation of microglia and pro-inflammatory mediators in animal models of PD under the reported treatments*.

*Mitigation/inhibition of microglial activation in animal models of PD under the reported treatments*.

*Enhanced neurogenesis/synaptic plasticity and glial proliferation*.

The chronic decrease of dopamine storage in the striatum is responsible for the gradual impairment of motor function leading to the classical motor features of PD, which include bradykinesia, rest tremor, rigidity and postural instability. These motor signs are often preceded by nonmotor manifestations such as olfactory dysfunction, autonomic, cognitive and mood function impairments (Langston, [@B114]).

The causes and mechanisms leading to the progressive and selective mDA neuron death are ill-defined, and so far, there is no cure for PD. Current treatments are centered on dopamine replacement therapy, using the metabolic precursor of dopamine, L-DOPA, or dopamine receptor agonists, albeit they only temporally alleviate the motor symptoms without stopping the ongoing neurodegeneration (Olanow and Schapira, [@B162]; Obeso et al., [@B158], for a comprehensive review). Thus, the ideal therapeutic regimen for PD should combine both symptomatic treatment and neurorestorative interventions aimed at protecting or enhancing the function of DA neurons.

The disease can be divided into sporadic and early-onset familial PD with most (90%) PD cases being sporadic (Ferreira and Massano, [@B60]) and current evidence indicates that a complex interplay between genetic susceptibility and a panel of environmental factors strongly contribute to PD pathophysiology (Di Monte et al., [@B50]; Gao and Hong, [@B67], [@B68]; Gao et al., [@B69], [@B70]; Marchetti et al., [@B140]; Cannon and Greenamyre, [@B27]; Hirsch et al., [@B90]; Table [1](#T1){ref-type="table"}). Indeed, several genes and many environmental factors impact in the regulation of crucial pathways involved in inflammatory glial activation, mitochondrial function, endoplasmic reticulum stress, autophagic catabolism, protein misfolding and aggregation, that can variously impact in the progressive demise of mDA neurons (Olanow et al., [@B163]; Abou-Sleiman et al., [@B1]; Marchetti et al., [@B140]).

Aging represents the chief risk factor for PD development. With advancing age the function of the nigrostriatal DA system progressively declines leading to neurochemical, morphological and behavioral changes (Boger et al., [@B21]; Hindle, [@B88]; de la Fuente-Fernández et al., [@B45]). Additionally, while nigrostriatal DA neurons are endowed with an extraordinary compensatory/neurorepair capacity, the aging process sharply impair DA neuron plasticity and its ability to recover upon injury (Collier et al., [@B39]).

Notably, oxidative stress and low-grade inflammation are the hallmarks of aging, and both processes are even further up-regulated upon injury, neurotoxin exposure, male gender and PD genetic mutations (Table [1](#T1){ref-type="table"}). With age, microglial cells become "primed," i.e., capable to produce exacerbated levels of a set of pro-inflammatory mediators when challenged with immune or neurotoxic stimuli. This microglial cell shift to the harmful, M1 phenotype, promotes the release of an array of factors that are detrimental for the vulnerable mDA neurons. Nuclear factor κB (NF-κB), is a key actor and the first signal for inflammasome induction (Codolo et al., [@B38]), together with major pro-inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) and IL-6. This inflammatory microenvironment is also associated to oxidative stress mediators such as reactive oxygen (ROS) and nitrogen species (RNS), that in turn amplify microglial activation, which results in increased mDA neuron vulnerability, and/or neuronal death (Olanow et al., [@B163]; Abou-Sleiman et al., [@B1]; Hirsch and Hunot, [@B89]).

Notably, a number of genetic mutations interact with certain risk factors, such as exposure to neurotoxins or endotoxins, then resulting in a further exacerbation of glial activation. In this condition, gene-environment interactions may drive a vicious cycle of oxidative stress and inflammation, contributing to the chronic PD progression (Di Monte et al., [@B50]; Marchetti and Abbracchio, [@B137]; Zhang et al., [@B231]; Whitton, [@B218], [@B219]; Gao and Hong, [@B67], [@B68]; Przedborski, [@B178]; Tansey and Goldberg, [@B200]; Gao et al., [@B69], [@B70]; Lastres-Becker et al., [@B117]; Table [1](#T1){ref-type="table"}).

Furthermore, crosstalks between central and peripheral inflammation together with changes in hormonal background with age, may well have further important roles in shaping the final glial response with consequences for neuroprotection/degeneration upon injury (Baba et al., [@B6]; Marchetti and Abbracchio, [@B137]; Brochard et al., [@B25]; Marchetti et al., [@B140]; Collins et al., [@B40]; Kannarkat et al., [@B102]; Chen et al., [@B32]).

We recently provided evidence that the Wnt/β-catenin signaling pathway, a chief player in neurodevelopmental processes (Ciani and Salinas, [@B35]; Clevers, [@B36]; Prakash and Wurst, [@B177]; Salinas, [@B183]; Joksimovic and Awatramani, [@B98]; Wurst and Prakash, [@B223]; Zhang et al., [@B227]), is crucially involved in the physiopathology of nigrostriatal DA neurons (L\'Episcopo et al., [@B126],[@B123]; Marchetti et al., [@B141]; Harvey and Marchetti, [@B84]). Furthermore, growing evidence indicates the contribution of Wnt signaling in the modulation of inflammation via bidirectional glia-neuron crosstalk in PD (L\'Episcopo et al., [@B126],[@B123], [@B130],[@B131]; Marchetti and Pluchino, [@B138]; Marchetti et al., [@B141]; Figure [1](#F1){ref-type="fig"}). Then, astrocytes and macrophage/microglial cells in the brain, and immune cells in the periphery express Wnts and harbor a panel of Wnt\'s receptors thereby modulating in an autocrine/paracrine fashion immune responses both at central and peripheral levels (Staal et al., [@B196]; Pereira et al., [@B167]; Neumann et al., [@B155]; Halleskog et al., [@B79], [@B78]; Kilander et al., [@B104]; L\'Episcopo et al., [@B126], [@B128], [@B129], [@B130]; Halleskog and Schulte, [@B80],[@B81]; Marchetti and Pluchino, [@B138]). In turn, Wnt receptors are present in mDA neurons and Wnt/β-catenin signaling activation exert robust neuroprotective effects (L\'Episcopo et al., [@B126],[@B123], [@B128], [@B129], [@B130],[@B131]; Harvey and Marchetti, [@B84]; Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}).

![Schematic illustration of gene-environment interactions impacting in mDA neuron survival/protection in the adult midbrain via Wnt1/β-catenin signaling. Major environmental factors including aging, inflammation, neurotoxin exposure including PD neurotoxins (MPTP/MPP+, 6-OHDA), pesticides (rotenone), increased oxidative load as a result of gowth factors (GFs) deprivation in synergy with genetic mutations (see Table [1](#T1){ref-type="table"}), may antagonize Wnt/β-catenin signaling ("*Wnt off* ") in mDA neurons. Up-regulation of active GSK-3β, then lead to β-catenin degradation and increased DA neuron vulnerability/degeneration/apoptosis. By contrast, in the intact midbrain canonical Wnt agonists, such as *Wnt1, Rspo* or *Norrin*, and activation of *Fzd-1* receptors also via exogenous Wnt/β-catenin activation such as GSK-3β antagonist, NO-NSAIDs treatments tors ("*Wnt on*"), contribute to maintain the integrity of mDA neurons via blockade of GSK-3β-induced phosphorylation (P) and proteosomal degradation of the neuronal pool of β-catenin. Stabilized β-catenin can translocate into the nucleus and associate with a family of transcription factors and regulate the expression of Wnt target genes involved in DA neuron survival/plasticity, neuroprotection and repair. β-catenin may also function as a pivotal defense molecule against oxidative stress, and can act as a coactivator for several nuclear receptors involved in the maintenance/protection of DA neurons. The hypothetical contribution of various endogenous Wnt agonists (Respondin, Rspo, Norrin) or antagonists (*Dkkopf, Dkk1, Wif*, frizzled-related proteins, SFRp) are also indicated.](fnagi-10-00012-g0001){#F1}

![Wnt/β-catenin signaling-induced switch in proinflammatory microglial M1 phenotype in concert with gene-environment interactions in PD. Upon activation by neurotoxins, endotoxins or brain injury and aging, macrophage/microglia produce a panel of pro-inflammatory cytokines (TNF-α and IL-1β) and chemokines (CCL3, CXCl10 and CXCL11), of which Wnt5a constitutes one part of a self-perpetrating cycle, via autocrine Wnt5A/CamKII activation and paracrine stimulation of Th-1- cytokines, iNOS and COX2 (Pereira et al., [@B167]; Neumann et al., [@B155]; Halleskog et al., [@B78]). Up-regulation of microglial PHOX-derived ROS, iNOS-derived NO, and GSK-3β, a known regulator of NF-kB-dependent gene transcription, further exacerbate microglia reaction (Beurel et al., [@B17]; L\'Episcopo et al., [@B128], [@B129]). In addition, astrocyte-derived growth/neurotrophic and anti-oxidant factors including Wnt1, can mitigate the inflammatory milieu and favor a progressive neurorescue program for mDA neurons (Marchetti et al., [@B141]). However, an exaggerated M1 microglial pro-inflammatory status as observed with age, MPTP exposure, and synergy with different gene and environmental risk factors can impair astrocyte anti-inflammatory and neuroprotective functions also via inhibition of Wnt1 expression and downregulation of anti-oxidant/anti-inflammatory cytoprotective proteins in astrocytes (L\'Episcopo et al., [@B129]). Modified from Marchetti and Pluchino ([@B138]), with permission.](fnagi-10-00012-g0002){#F2}

Microglia and astrocyte-microglia crosstalk also modulate the brain\'own regenerative/neurorestorative potential, regulating adult neural stem/progenitor cell (NSC) plasticity in neurogenic niches (Pluchino et al., [@B171]; Jakubs et al., [@B97]; Ekdahl et al., [@B56]; Schwartz et al., [@B188]; Ehninger et al., [@B54]; Ekdhal, [@B57]; Kokaia et al., [@B109]; L\'Episcopo et al., [@B128], [@B129]; Marchetti and Pluchino, [@B138]). However, aging, inflammation and PD, exacerbating microglia M1 phenotype impair NSCs proliferation and neuronal differentiation and inhibit Wnt/β-catenin signaling (Freundlieb et al., [@B65]; Okamoto et al., [@B161]; L\'Episcopo et al., [@B128]; [@B129]), with harmful consequences for mDA neuron recovery and repair upon injury (L\'Episcopo et al., [@B129], [@B130],[@B131]; Figure [3](#F3){ref-type="fig"}).

![Aging-induced M1 proinflammatory phenotype promotes *Nrf2-ARE* pathway disruption in the subventricular zone (SVZ) driving neurogenic impairment in parkinsonian mice via *PI3K-Wnt/*β*-catenin* dysregulation. In young mice a regulatory circuit linking microglial activation and pro-inflammatory cytokine to *Nrf2-ARE* protective pathway in SVZ, provides an efficient self-adaptive mechanism against inflammatory/neurotoxin-induced oxidative stress. In addition to govern the redox balance within the SVZ niche, *Nrf2*-induced *Hmox* target gene may simultaneously protect astrocytes, thereby up-regulating the expression of vital *Wnt* signaling elements switching-on key components required for maintaining SVZ cells in a proliferative state, promote differentiation and/or for exerting neuroprotective effects. Crosstalk between two pivotal pathways, the *PI3-K/Akt/GSK-3*β and *Wnt/*β*-catenin* signaling cascades appear to cooperate to finely control the transcriptional activator, β*-catenin*, in turn representing a point of convergence to direct proliferation/differentiation/survival in SVZ stem niche. Importantly, SVZ "rejuvenation" may have beneficial consequences for DAergic neuroprotection, and viceversa. Astrocytes (blue), neuroblasts (red), transit-aplifying cells (yellow) and ependymal (purple) cells in SVZ niche are schematically illustrated (modified from L\'Episcopo et al., [@B129], with permission).](fnagi-10-00012-g0003){#F3}

Recently, in several neurodegenerative diseases, including PD, a dysregulation of non-coding RNAs (ncRNAs) levels has been reported (Sonntag, [@B193]). MicroRNAs (miRNAs) are the most studied class of ncRNAs, which play key roles in normal cellular physiology as well as in pathogenesis, including PD pathogenesis (Bartel, [@B9]; Soifer et al., [@B192]; Bian and Sun, [@B18]). Of special importance for the present work, different miRNAs are increasingly being appreciated for their ability to modulate the microglial inflammatory response in PD, with novel potential therapeutic implications for regulating the inflammatory response during PD progression (Thome et al., [@B204]).

In this work we will first introduce the role of neuroinflammation in PD, with a specific focus on microglia-astrocyte-neuron crosstalk. Particularly, the role of gene-environment interactions such as aging, neurotoxins and inflammogen exposure and their influence in microglial polarization and Wnt signaling together with the interplay between mRNAs and miRNA modulatory effects will be next addressed.

Neuroinflammation and PD: the key role of microglial-astrocyte-neuron tripartite crosstalk {#s2}
==========================================================================================

A body of evidence from epidemiological and post-mortem studies in human PD brains, coupled to accumulating data in experimental models of PD in either non-human primates and rodent PD models, clearly indicates that neuroinflammatory glial-mediated mechanisms are chiefly involved in PD pathophysiology, playing a dual benefical/harmful role (Marchetti and Abbracchio, [@B137]; Marchetti et al., [@B139],[@B143],[@B144]; McGeer and McGeer, [@B146]).

Although the "primum movens" initiating the inflammatory response and the causal relationship between the two phenomena remain to be fully clarified, it is recognized that neuronal degeneration itself, particularly aggregated α-Syn (a core feature of both sporadic and familial forms of PD) (Bendor et al., [@B11]), released early in the disease process by the injured DA neurons, may act as an endogenous disease-related signal, activating glial cells to release a variety of pro-inflammatory molecules, promoting microglia exacerbation and neuronal cell death (Zhang et al., [@B231]; Whitton, [@B218]; Gao et al., [@B69]; Codolo et al., [@B38]; Sanchez-Guajardo et al., [@B184]). In turn, neuroinflammatory glial activation has been suggested also to contribute via the promotion of a prion-like behavior of misfolded α-Syn propagation (Lema Tomé et al., [@B120]).

The possibility that an early dysregulated microglial pro-inflammatory phenotype contributes to progressive nigrostriatal degeneration in PD has received increasing attention in the light of the implications for preventive and therapeutic strategies for PD (Marchetti and Abbracchio, [@B137]; Zhang et al., [@B231]; Whitton, [@B218], [@B219]; Gao and Hong, [@B67]; Koprich et al., [@B110]; Hirsch and Hunot, [@B89]; Deleidi et al., [@B46]; L\'Episcopo et al., [@B125],[@B124], [@B127]). Hence, positron emission tomography imaging studies employing microglia-specific markers support an early involvement and cerebral propagation of neuroinflammation in PD (Gerhard et al., [@B72]; Ouchi et al., [@B165]; Pradhan and Andreasson, [@B175]). Prospective studies suggest that inflammatory processes can modulate PD risk in humans, as higher plasma concentrations of the pro-inflammatory cytokine interleukin-6 (IL-6) increased the risk of developing PD whereas chronic nonsteroidal anti-inflammatory drug (NSAID) regimens reduced the incidence of PD by 46% (Chen et al., [@B30], [@B29]; Schiess, [@B187]). Importantly, the association of late-onset sporadic PD with certain genetic variants in the region of chromosome 6 that specifies the human leukocyte antigens (HLAs), which are crucial for immune function in humans (Hamza et al., [@B82]), have been further strengthened using Genome-wide association studies (GWAS) (Latourelle et al., [@B118]). Especially, meta-analyses by the International Parkinson Disease Genomics Consortium et al. ([@B96]), supported the evidence for association of five previously reported risk loci near the genes for alpha-synuclein (*SNCA*), microtubule associated protein tau (*MAPT*), cyclin G-associated kinase (*GAK*), beta-glucocerebrosidase (*GBA*), and *HLA* locus (HLA).

Consistent with the inflammation hypothesis, experimental evidences in different PD rodent models indicate significant neuroprotective effects exerted by different immunomodulatory drugs including non steroidal anti-inflammatory drugs (NSAIDs). However, there are some conflicting results in the ability of the different NSAIDs to effectively protect mDA neurons against neurotoxic insults, likely due to the dual (beneficial/harmful) effects of inflammation, the timing of the NSAID treatment (i.e., before or after mDA neuron injury), and the specific properties of the different NSAIDs (reviewed by Marchetti and Abbracchio, [@B137]; Fiorucci and Antonelli, [@B61]; Esposito et al., [@B59]; Whitton, [@B218], [@B219]; L\'Episcopo et al., [@B125],[@B124], [@B127]; Pradhan and Andreasson, [@B175]).

Within this scenario the major players are the microglial cells, the reactive astrocytes, and the infiltrating monocyte-derived macrophages (Depboylu et al., [@B48]). Notably, microglia are highly pleiotropic cells and dynamically shift between a quiescent (termed M2)-to moderate or highly activated (termed M1) states, depending on the triggering mechanisms and the duration of the insult (Kreutzberg, [@B111]; Streit, [@B197]; Perry and Teeling, [@B168]). In the basal M2 state, microglia have anti-inflammatory and neuron-reparative roles, protecting neighboring cells by removing cell debris and releasing trophic factors for brain repair. Upon injury or immune challenges, activated M1 microglia proliferate and participate in clearing cell debris at early stages, but may exacerbate brain injury by producing neurotoxic substances, especially when overactivated for prolonged times (Perry and Teeling, [@B168]). In these conditions, microglia release a variety of pro-inflammatory mediators that can become detrimental to neuronal survival. Major players are the transcription factor NF-κB and activator protein-1 (AP-1) chiefly involved in the induction of multiple inflammatory genes involved in the inflammatory response. Particularly, among glial cytotoxic molecules, inducible NO synthase (iNOS)-derived NO, superoxide from the plasma membrane NADPH oxidase, cyclooxygenase 2 (COX2)-derived prostaglandin E2, associated with a number of potent inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IFN-γ shown to exert detrimental effects in mDA neurons (Sriram et al., [@B194], [@B195]; Teismann et al., [@B202]; Whitton, [@B218], [@B219]; Gao and Hong, [@B67]; Hirsch and Hunot, [@B89]).

As astrocytes are concerned, they are prominent players both in health and disease (Sofroniew and Vinters, [@B191]). They contribute to a panel of key functions in the CNS, including the provision of trophic support to neurons, clearance of debris, as well as the modulation of synapse formation and function, energy metabolism, and in particular the defense against oxidative stress (see Bélanger and Magistretti, [@B10]). For example, efflux of GSH from astrocytes mediated by the ATP-dependent transporter, multidrug-resistance associated protein (Mrp1) is involved in the dynamic response to the changing redox mileu (Gennuso et al., [@B71]). The expression and activation of anti-oxidant response element (ARE) represent a key feature of astrocyte neuroprotective effects. Oxidative stress can up-regulate enhance expression and binding of astrocytic NF-E2-related factor 2 (*Nrf2*), which translocates to the nucleus and binds to ARE. Importantly, binding to ARE up-regulates a cluster of anti-oxidant genes, including those for GSH, as well as anti-oxidant, anti-inflammatory and cytoprotective genes, such as *Heme oxygenase1* (*Hmox*) (Chen et al., [@B31]).

Astrocytes\' modulation of the local microenvironment is complemented by the expression and release of a variety of growth and neurotrophic factors and a number of pro/anti-inflammatory mediators and anti-oxidant molecules (see Marchetti et al., [@B141]). Furthermore, astrocytes can contribute to cell genesis both as stem cells and as important cellular elements of the neurogenic microenvironment, with implications for self-recovery/neurorepair (Alvarez-Buylla et al., [@B3]). Upon injury, astrocytes can transform into "reactive" astrocytes (Ras), that can fulfill both neuroprotective or neurotoxic functions. Ras are characterized by up-regulation of several molecules including GFAP and S100, they express receptors involved in innate immunity (e.g., Toll-like receptors), participating in the regulation of astrocyte response to injury. In addition, Ras express receptors for growth factors, chemokines, hormones, and produce a wide array of chemokines and cytokines that act as immune mediators in cooperation with those produced by microglia (Marchetti et al., [@B139],[@B143]).

Thanks to the shared receptors for neurotransmitters, hormones, neuromodulators, neuropeptides and immune regulatory molecules, neurons, astrocyte and microglial cells can talk with each other and sense the changing microenvironment. Then, glial-neuron crosstalk is essential for maintaining CNS homeostasis during physiological, and particularly under neurodegenerative and inflammatory conditions. Especially, astrocyte-microglia crosstalk plays a pivotal role, aimed at reducing or inhibiting any exacerbated inflammatory/oxidative response in the brain (Bélanger and Magistretti, [@B10]; Marchetti and Pluchino, [@B138]). This appears of particular importance given that microglial cells in the SNpc are more abundant (about 4.5-fold) as compared to any other brain region, while SNpc-DA neurons have reduced anti-oxidant potential, and the redox chemistry of dopamine present in the cytoplasm could be enhanced by an exacerbation of ROS production, leading to the formation of toxic dopamine metabolites. All together these conditions predispose mDA neurons to vulnerability to inflammatory/oxidative attacks (Abou-Sleiman et al., [@B1]; Whitton, [@B218], [@B219]; McGeer and McGeer, [@B146]; Tansey and Goldberg, [@B200]; Taylor et al., [@B201]).

Consequently, the microglial M1 proinflammatory status is tightly linked to astrocyte-microglia and neuron-glia interactions through a number of mechanisms and a panel of inhibitory receptors that restrain microglial activation. For example, CD200, a transmembrane glycoprotein expressed on neurons, can survey glial activation status via its binding to CD200R (Wang et al., [@B216]; Zhang S. et al., [@B230]). When CD200-CD200R engagement is disrupted, this can lead to an abnormal activation of microglia and consequent pathological changes. Importantly, microglia harbor hormonal receptors (i.e., for glucocorticoid hormones, GRs, and for estrogens, ERs) contributing to limit microglial overactivation via the blockade of principal inflammatory pathways, particularly NFκB signaling and the iNOS-NO pathway generating elevated concentrations of proinflammatory cytokines and RNS (Marchetti et al., [@B142], [@B139],[@B143], [@B140]; Vegeto et al., [@B209]; Morale et al., [@B151], [@B150], [@B149]; L\'Episcopo et al., [@B125]).

Upon exposure to the PD neurotoxins including 6-OHDA- or MPTP, glia-neuron and astrocyte-microglia crosstalk play decisive roles in dicating the severity of the nigrostriatal lesion and the repair capacity of the dysfunctional mDA neurons, according to the SNpc microenviroment, the age and sex of the host. In humans and non-human primates exposed to MPTP, the presence of Ras in the SN lasts for 1--16 years following the initial insult, but the biological significance of Ras is not completely understood (Collier et al., [@B39]; Barcia et al., [@B8]). Of note, however, in the presence of chronic microglia over-activation, Ras can loose both neuroprotective and neurorepair properties with harmfull consequences for the dysfunctional mDA neurons. Hence, a prolonged dysfunction of astrocytes and activation of microglia can accelerate the degeneration of SNpc DA neurons, blocking the compensatory mechanisms of mDA neuron repair during early dysfunction induced by 6-OHDA lesion in rats, thus underlying the important role of astrocytes in early degeneration of mDA neurons (Kuter et al., [@B112]). Importantly enough, in analogy to the M1/M2 macrophage nomenclature, neuroinflammation and brain injury were shown to promote two different types of Ras termed A1 and A2, with the A1-Ras phenotype promoting destructive effects, and the A2 state exerting neuroprotective roles (Liddelow et al., [@B132]). Then, when stimulated by LPS, activated M1 microglia secreting proinflammatory cytokines, such as IL-1β and TNF- α, contribute to the promotion of the Ras A1 phenotype leading to the inhibition of astrocyte\'s ability to promote neuronal survival, outgrowth, synaptogenesis and phagocytosis, and to induce the death of neurons and oligodendrocytes (Liddelow et al., [@B132]).

As far as the cytotoxic mechanism(s) involved in mDA neuron death, of specific mention, when iNOS and NADPH oxidase are present together, then a potent toxin, peroxynitrite (ONOO-), is produced which promotes the nitration of proteins, like tyrosine, with further production of hydroxyl radicals. For example, the production of the free radical NO together peroxynitrite are sought to be involved in mDA neuron demise (Gao and Hong, [@B67]; Hirsch and Hunot, [@B89]; Taylor et al., [@B201]). Regarding the cytokines, TNF-α can directly activate TNF receptors (TNF-Rs) present on mDA neurons and trigger a pro-apoptotic cell death pathway. Also, the TNF-α-dependent proinflammatory microenvironment within the SN is further amplified by increased oxidative stress through activation of PHOX, the expression of COX-2 and the stimulation of iNOS. The resulting production of ROS, RNS, excitotoxic mediators, such as glutamate and a panel of reactive molecules, further amplify the inflammatory reaction engendering a vicious cycle, resulting in the exacerbation of the neurodegenerative process (Whitton, [@B218]; More et al., [@B152]).

Importantly enough, both microglia and astrocytes are dysfunctional with advancing age. Hence both cell types show region-specific changes in morphology such as structural deterioration or dystrophy, decreased expression of growth/neurotrophic factors and an impaired phagocytic activity in face of increased marker expression and up-regulation of pro-inflammatory molecules, all of which are associated to a gradual loss of astrocyte and microglia neuroprotective capacity (Mouton et al., [@B154]; Streit et al., [@B199]; Morale et al., [@B150]; Damani et al., [@B44]; L\'Episcopo et al., [@B127]; Njie et al., [@B157]). Reportedly, microglial switch to a so-called "primed" status, endowed with a strong neurotoxic, pro-inflammatory M1 phenotype (Streit, [@B198]; Njie et al., [@B157]) with cytotoxic influences for mDA neuron health (L\'Episcopo et al., [@B127]).

Especially, work from our laboratory indicates that age-dependent changes in the glial compartment results in a dysregulation of glia-neuron crosstalk and play key roles in the impairment of nigrostriatal DA plasticity (L\'Episcopo et al., [@B126],[@B123],[@B127]). In fact, increased vulnerability and mDA neuron death are observed after exposure of aging mice to neurotoxin or inflammatory triggers, supporting that glia dysfunction with age represents a primary risk factor and a common final pathway for neurodegenerative disorders in general and for PD in particular (L\'Episcopo et al., [@B125],[@B124]). Notably, mDA neuron numbers and striatal innervation as well as DA release and motor deficits show a remarkable ability to recover after acute or chronic administration of MPTP or 6-OHDA in young rodents and non-human primates, but this adaptive capacity is lost with age (Collier et al., [@B39]; Boger et al., [@B21]; Hindle, [@B88]; de la Fuente-Fernández et al., [@B45]; L\'Episcopo et al., [@B126],[@B123]; Blandini and Armentero, [@B20]; Bové and Perier, [@B23]).

In addition to glial cells, other cells may also participate in the neuroinflammatory processes in PD, as increasing evidence demonstrates the involvement of both innate and adaptive immune responses in the pathophysiology of PD (Baba et al., [@B6]; Orr et al., [@B164]; Brochard et al., [@B25]; Collins et al., [@B40]; Kannarkat et al., [@B102]; Chen et al., [@B32]). The infiltration of CD4/CD8 T-cells has been reported both in the SN of PD patients and in animal models of PD, together with alterations in the peripheral T-cell pool is altered in PD, with potential interactions with the local SN microglial environment promoting further exacerbation of M1 phenotype (Brochard et al., [@B25]; Barcia et al., [@B8]; reviewed by Sanchez-Guajardo et al., [@B184]). Cytokine and chemokine expression are also upregulated in peripheral blood mononuclear cells (PBMCs) in PD patients.

Of specific mention, with age, there is an up-regulation of several inflammatory markers in the periphery associated to a dysfunctional blood-brain barrier (BBB), resulting in increased crosstalk between the CNS and peripheral immune system (Cunningham et al., [@B41]). This increased sytemic proinflammatory status may then trigger inflammatory glial responses, associated to an exaggerated production of various inflammatory molecules such as TNF-α, IL-1β, coupled to production of high levels of ROS and RNS, promoting a vicious cycle of oxidative stress and inflammation leading to neuronal death (Streit et al., [@B199]; Cunningham et al., [@B41]; Flanary, [@B62]; Godbout et al., [@B75]; Flanary et al., [@B63]; Hu et al., [@B94]; Pott Godoy et al., [@B174]; Henry et al., [@B87]; Damani et al., [@B44]; L\'Episcopo et al., [@B125],[@B124], [@B127]; Streit, [@B198]; Njie et al., [@B157]). Hence, young adult and aging mice respond in a strikingly different way when an acute subthreshold dose of LPS was systemically administrated, as a single LPS injection in old mice resulted in exacerbated production of pro-inflammatory markers both at central and peripheral levels. This general proinflammatory status then triggered a slow but progressive mDA neuron loss during the entire lifespan of the mice (L\'Episcopo et al., [@B127]). By contrast, the concomitant treatment with the NO-releasing NSAID, Flurbiprofen (NO-Flurbi) (Fiorucci and Antonelli, [@B61]) was capable to mitigate the exacerbated M1 microglia pro-inflammatory phenotype induced by the systemic neurotoxic challenge, resulting in a lifelong protection of SNpc DA neurons (L\'Episcopo et al., [@B127]; Figure [2](#F2){ref-type="fig"}).

All together these findings support the contention that glia-neuron crosstalk in the brain, complemented by a proinflammatory status at peripheral levels, may represent a major risk factor and final common pathway for mDA neuron vulnerability to PD degeneration. Additionally, they provide a mechanistic link between microglial M1 pro-inflammatory status of aging mice, microglia-DA neuron crosstalk and DA cell demise, and offer a therapeutical window of opportunity to rescue mDA neurons from inflammation-mediated neurodegeneration of old mice by targeting the microglial pro-inflammatory phenotype (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Within this frame, the role of astrocytes clearly appear decisive, since they can either cooperate with microglia to exacerbate M1 phenotype and the consequent neurotoxicity, or in the contrary, they can downregulate microglia activation, to support the imperiled/dysfunctional mDA neurons and activate intrinsic cues for DA neuroprepair/neurorestoration (Marchetti et al., [@B141]; L\'Episcopo et al., [@B130],[@B131]).

The Wnt/β-catenin signaling pathway: a "new entry" in glia-neuron dialogue {#s3}
==========================================================================

Emerging evidence of the last decades points to *Wingless-type MMTV integration site* (*Wnt*) signaling, a highly conserved pathway across species, as a crucial regulator of a multitude of CNS functions both during development and in the adult brain. Here we will first introduce briefly Wnt signaling and the pathways operating at the mDA neurons, astrocytes and microglial levels.

Wnts are secreted lipid-modified glycoproteins that regulate stem cell self-renewal, differentiation, and cell-to-cell communication during embryonic development and in adult tissues. The activation of Wnt signaling is a complex and well regulated process that relies on the expression of a specific Wnt ligand, the concomitant presence of endogenous/exogenous Wnt signaling regulators, the expression of a particular subtype of Frizzled (Fzd) family receptors, the coreceptors, and the specific cellular context (Gordon and Nusse, [@B76]; Angers and Moon, [@B4]; Salinas, [@B183]; van Amerongen, [@B207]; Willert and Nusse, [@B220]; and Wnt homepage: <http://www.stanford.edu/~rnusse/wntwindow.html>). There are 19 mammalian Wnt genes and 15 receptors and co-receptors distributed over seven protein families in mammals (Niehrs, [@B156]). Wnt proteins are recognized to activate two major branches of Wnt signaling pathways, the so called "canonical" Wnt/β-catenin (activated by the *Wnt1* class of ligands, Wnt2, Wnt3, Wnt3a, Wnt8, and Wnt8a) and the "non-canonical" that includes the Wnt/PCP and Wnt/Ca^2+^ pathways (activated by Wnt5a class, that includes Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, and Wnt11) (Willert and Nusse, [@B220]). However, such description appears an oversimplification, since in some instances a same Wnt ligand can activate different pathways depending on the presence of the receptors and coreceptors, the endogenous activators or inhibitors, as well as the specific cellular context. While a detailed discussion of Wnt signaling components is beyond the scope of this work (see Marchetti and Pluchino, [@B138]), we will summarize the principal actors of Wnt/β-catenin pathway, the most well-characterized Wnt pathway that plays a vital role in mDA neurodevelopment, mDA neuroprotection and regeneration (Harvey and Marchetti, [@B84]; Figure [1](#F1){ref-type="fig"}).

Notably, in the canonical Wnt pathway, β-catenin and GSK3β (glycogen synthase kinase 3β) are the key players (Clevers and Nusse, [@B37]). When specific Wnt1-like ligands are absent (i.e., in the "*Wnt off"* state), the concentration of cytoplasmic β-catenin is maintained at low levels via the constant targeting by a multiprotein destruction complex, composed of two scaffold proteins, Axin and APC (adenomatous polyposis coli), which support the phosphorylation of β-catenin by CK1α (casein kinase 1 α) and GSK3β. As a next step, the phosphorylation of β-catenin results in its recognition and ubiquitination by the E3 ubiquitin ligase β-TrCP (β-transducin repeats containing protein), leading to β-catenin proteasomal degradation. Under such conditions, the nuclear transcription factor lymphoid enhancer-binding factor/T cell-specific (LEF/TCF) is associated with Groucho and represses target gene expression (Roose et al., [@B180]). In the "*Wnt off* " state, the phosphorylation of β-catenin in mDA neurons negatively impact both in the survival and protection against a variety of noxious insults (L\'Episcopo et al., [@B126],[@B123]; Figure [1](#F1){ref-type="fig"}, and next section).

By contrast, binding of Wnt1-like ligands to Fzd receptor and its co-receptor to the low-density LRP (lipoprotein receptor-related protein)5/6 (i.e., in the "*Wnt on"* state), this results in the formation of large multiprotein aggregates (Bilic et al., [@B19]), called signalosomes, that are involved in the prevention of β-catenin proteasomal degradation (Zeng et al., [@B226]). Hence, the kinase activity of GSK3-β is inhibited, leading to the stabilization of cytosolic β-catenin, which then accumulates and translocates to the nucleus to regulate transcription via transcription factor then the TCF/LEF family (Clevers, [@B36]). Nuclear β-catenin then displaces Groucho and forms a complex with tissue-specific transcriptional activators, and converts LEF/TCF from a transcriptional repressor to an activator that turns on Wnt-dependent gene expression in a very cell-type-specific manner (Mosimann et al., [@B153]; Cadigan and Waterman, [@B26]). In mDA neurons, nuclear β-catenin activates Wnt1-dependent genes involved in mDA neuron specification, survival and protection (L\'Episcopo et al., [@B126],[@B123], [@B128], [@B129], [@B130],[@B131]; Wei et al., [@B217]; Figure [1](#F1){ref-type="fig"}).

Notably, GSK-3β is a serine/threonine protein kinase, that besides its central role in the Wnt/β-catenin pathway, is recognized to play key roles in a variety of cellular processes via a panel of signaling pathways that are crucial for inflammation and oxidative stress, cell proliferation, stem cell renewal and apoptosis/neuronal survival, amongst others (Grimes and Jope, [@B77]; Jope et al., [@B99]; Kim et al., [@B107]; Beurel et al., [@B17]; Phukan et al., [@B170]; Beurel, [@B16]; Kim and Snider, [@B106]; King et al., [@B108]). Especially, in the "Wnt off" state, activation of GSK-3β in mDA neurons represents a critical step in SNpc neuron demise upon MPTP-induced neuronal cell death both *in vitro* and *in vivo* (Chen et al., [@B28]; Duka et al., [@B51]; Petit-Paitel et al., [@B169]; L\'Episcopo et al., [@B126],[@B123]). Additionally, in glial cells, Wn/β-catenin antagonism results in GSK-3β activation and exacerbation of glia activation associated to the production of proinflammatory mediators with consequent glial-dependent neurotoxicity (L\'Episcopo et al., [@B122] and discussed in next sections).

The β-catenin independent, so called "*non canonical*" Wnts ligands, signal through Fzd receptors as well as members of the receptor tyrosine kinase-like orphan receptor (Ror) family and the Wnt modifier, receptor-like tyrosine kinase (Ryk). This pathway leads to changes in cell polarity and migration and is mediated by Ca^2+^influx as well as activation of the small GTPases, RhoA, Cdc42 and Rac (van Amerongen et al., [@B208]; Angers and Moon, [@B4]; van Amerongen, [@B207]). However, such classifications are not rigid since these pathways can overlap or influence/crosstalk or antagonize β-catenin-dependent signaling, thereby constituting a further regulatory step in the control of Wnt signaling (Angers and Moon, [@B4]; Glinka et al., [@B74]).

Remarkably, approximately 400 genes involved in cell growth, differentiation, apoptosis, survival and immune functions are regulated by the Wnt/β-catenin signaling, and in view of its multifunctional roles, this pathway is counter-modulated by different endogenous regulators which include the *Dickkopf* (*Dkk)* family (*Dkk-1*, -2, -3, and -4 and soggy), and secreted frizzled-related proteins (Sfrps) considered as both negative and positive Wnt signaling regulators (Bovolenta et al., [@B24]; van Amerongen et al., [@B208]; Angers and Moon, [@B4]).

All together, potential interactions between Wnt ligands, their receptors and downstream effectors, coupled to crosstalks between the *canonical* and *non-canonical* branches of Wnt signaling anticipates the level complexity of the Wnt signaling machinery. Furthermore, given the in involvement of Wnt signaling in a multitude of developmental processes and the maintenance of adult tissue homeostasis, not surprisingly, an aberrant regulation of this pathway has been linked with a variety of diseases, including cancer, inflammatory, metabolic, or neurodegenerative diseases (Clevers and Nusse, [@B37]).

The Wnt1/β-catenin-inflammatory connection for mDA neuroprotection, neurorepair and neurorestoration {#s4}
====================================================================================================

Wnt1 is a unique critical morphogen for mDA neurodevelopment and activation of the Wnt1/β-catenin signaling is required for mDA neuron specification (Arenas, [@B5]; Joksimovic and Awatramani, [@B98]; Wurst and Prakash, [@B223]; Toledo et al., [@B206]). This chief role of Wnt1 is maintained throught life in the adult midbrain, where Wnt1 contributes to the maintenance of SNpc DA neuron survival, neuronal function and synaptic integrity, in promoting the activation of Nurr1^+^ post-mitotic mDA neuroprecursors, in favoring neuroprotection and neurorestoration in the injured PD midbrain and up-regulating adult neurogenesis in neurogenic niches, via glia-neuron and glia-NSCs crosstalk (Inestrosa and Arenas, [@B95]; L\'Episcopo et al., [@B126],[@B123], [@B128], [@B129], [@B130]; Galli et al., [@B66]; Harvey and Marchetti, [@B84]; Zhang et al., [@B227]).

Indeed, astroglial cells are a major source of Wnts and harbor a panel Fzd receptors, that play roles in bidirectional astrocyte-neuron and astrocyte-microglia crosstalk. Work from our laboratory obtained *in vivo* in rodent models of PD, as well as *in vitro*, in primary mesencephalic neuron-astrocyte and astrocyte-microglia coculture systems, indicates that during MPTP injury, in the inflammed midbrain, microglial-derived chemokines induce Wnt1 in astrocytes, and this Wnt1 up-regulation activates canonical Wnt/β-catenin signaling in mDA neurons (L\'Episcopo et al., [@B126]; Figure [1](#F1){ref-type="fig"}), as an intrinsic neurorescue response, in turn responsible for mDA neuroprotection against a variety of insults, such as oxidative stress and PD neuroxins (i.e., MPP+ or 6-OHDA) (L\'Episcopo et al., [@B126],[@B123]; Marchetti et al., [@B141]). Astrocyte-derived Wnt1 ability to promote neuroprotection is mimicked by specific GSK-3β antagonists and efficiently counteracted by down-regulating Wnt1 expression in astrocytes or inhibiting Wnt/β-catenin pathway activation in mDA neurons with either molecular (short hairpin RNA silencing Wnt1 in astrocytes, Fzd1-knock down with antisense-RNAs, β-catenin silencing in mDA neurons) or pharmacological approaches (inhibiton of Wnt/β-catenin signaling with Dkk1, Sfrps, or Wnt1-Abs, L\'Episcopo et al., [@B126],[@B123]; Marchetti et al., [@B141]).

However with the aging process, Wnt signaling declines, leading to dysfunctional neuron-astrocyte and astrocyte-microglia crosstalk (L\'Episcopo et al., [@B126],[@B123],[@B127], [@B129], [@B130]; Okamoto et al., [@B161]; Marchetti et al., [@B141]; Seib et al., [@B189]). Hence, the aged microglia proinflammatory status coupled to the exposure to PD neurotoxins markedly inhibit Wnt1 expression in midbrain astrocytes, with a concomitant downregulation of β-catenin and Fzd-1 receptors in mDA neurons, thereby counteracting both the neurotrophic and proneurogenic potential of astrocytes (L\'Episcopo et al., [@B126],[@B123],[@B127], [@B128], [@B129], [@B130],[@B131]).

Of special importance, activation of Wnt signaling also impact in glia functionality, given that Wnt signaling may both promote or down-modulate macrophage/microglial activation and the production of proinflammatory mediators. For example, the "*canonical"* Wnt-3a ligand, and the "*non canonical"* Wnt-5a, can both induce a pro-inflammatory response in primary mouse microglia, *in vitro* (Halleskog et al., [@B78]; Halleskog and Schulte, [@B80]). On the other hand, after LPS- induced proinflammatory transformation of microglia, both Wnt-3a and Wnt-5a exerted a dose-dependent decrease in the pro-inflammatory marker, COX2 (Halleskog and Schulte, [@B80]), thereby suggesting that the inflammatory microenvironment plays an important role in dictating the outcome of microglial response to Wnts (Marchetti and Pluchino, [@B138]).

Likewise, in peripheral macrophages, both Wnt-3a and Wnt-5a can drive a pro-inflammatory transformation with increased production of pro-inflammatory cytokines, such as TNF-α (Pereira et al., [@B167]). Of special interest, however, in *mycobacterium-* infected macrophages, Wnt-3a can reduce the exacerbated TNF-α levels through an autoregulatory feedback mechanism involving increased Fzd-1 receptors and activation of the Wnt/β-catenin pathway (Pereira et al., [@B167]; Neumann et al., [@B155]; Schaale et al., [@B186]). Additionally, Wnt-3a also promotes the expression of Arginase 1 in *M. tuberculosis-*infected macrophages, which has been associated with the anti-inflammatory M2 phenotype (Neumann et al., [@B155]).

Especially, crosstalk with inflammatory and oxidative stress pathways for the modulation of immune responses now highlights Wnt signaling as a critical modulator of M1/M2 pro/anti-inflammatory glial phenotype via both autocrine and paracrine effects (Chong and Maiese, [@B33]; Chong et al., [@B34]) (Figure [2](#F2){ref-type="fig"}). Work from our laboratory showed that during the acute mDA degeneration phase resulting from exposure to MPTP, microglia switches to M1 activated phenotype associated with up-regulated expression of NFκB and release of TNF-α and IL-1β cytokines, the up-regulation of PHOX-derived ROS and iNOS-derived NO and RNS, alltogether contributing to the acute loss of mDA cell bodies (L\'Episcopo et al., [@B126]; Figure [2](#F2){ref-type="fig"}). Another actor in glial activation cycle is represented by activation of the proinflammatory GSK-3β, leading to a vicious cycle of microglial activation (Jope et al., [@B99]; Beurel et al., [@B17]; Beurel, [@B16]; L\'Episcopo et al., [@B126],[@B123], [@B122]; Marchetti et al., [@B141]). Hence, NFκB and the Wnt/β-catenin pathway interact to differentially regulate inflammation: in a "*Wnt off"* condition, the activation GSK-3β positively regulates NFκB by targeting IkB (i.e., the major inhibitor of NFκB) to proteasomal degradation, which results in NFκB nuclear translocation and the induction of a proinflammatory genetic cascade, finally exacerbating microglia M1 phenotype (see Beurel et al., [@B17]; Neumann et al., [@B155]; Beurel, [@B16]). By contrast, in the "*Wnt On*" condition, cytosolic β-catenin accumulation can form a complex with the p50 subunit of NFκB, resulting in the prevention NF-kB transcriptional activity with consequent switch to the M2 microglia phenotype and downregulation of inflammation (Figure [2](#F2){ref-type="fig"}).

It seems important to note that the harmful M1 phenotype can itself promote an intrinsic Wnt/β-catenin rescue program both in neurons and glia. Hence, through glial expression of specific chemokines, such as CCL3, CXCl10, and CXCL11, astrocyte-derived Wnt1 is significantly up-modulated, both a mRNA and protein levels, and a progressive time-dependent neurorepair of nigrostriatal DA neurons and downregulation ofinflammation is observed (L\'Episcopo et al., [@B126]). Then, via astrocyte-microglia crosstalk and the release of Wnt1-like proteins in astrocytes, the resulting Wnt/β-catenin activation in microglial cells can inhibit GSK-3β activation, resulting in a downregulation of proinflammatory mediators (Chong and Maiese, [@B33]; Maiese et al., [@B136]; L\'Episcopo et al., [@B126],[@B123], [@B129], [@B131]; Schaale et al., [@B186]; Wang et al., [@B214]; Marchetti and Pluchino, [@B138]; Figure [2](#F2){ref-type="fig"}). In fact, the pharmacologic antagonism of GSK-3β restrain inflammatory microglial activation via the inhibition of proinflammatory cytokines through interactions at the level of NFκB (Beurel et al., [@B17]; Beurel, [@B16]; L\'Episcopo et al., [@B126],[@B123]; Marchetti et al., [@B141]; Figure [2](#F2){ref-type="fig"}).

All together, an exaggerated microglial pro-inflammatory M1 status as observed with age and MPTP exposure, can impair astrocyte anti-inflammatory functions and mDA neurorescue (L\'Episcopo et al., [@B126],[@B123],[@B127]), via inhibition of Wnt1 expression and downregulation of anti-oxidant/anti-inflammatory cytoprotective proteins in astrocytes (L\'Episcopo et al., [@B129]; Marchetti et al., [@B141]; Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}).

Astrocyte-microglia crosstalk and neural/stem progenitor cell (NSC) plasticity: Wnt signaling and inflammatory pathways shape the SVZ response to advancing age and PD {#s5}
======================================================================================================================================================================

With age, the brain homeostatic and regenerative capacities progressively decline, at least in part as a result of a reduced tissue-specific self-adaptive potential and an impairment and/or a dysregulation of stem cell activity. Hence, a common hallmark in a number of age-dependent neurodegenerative diseases appears to be an alteration of adult neurogenesis (Curtis et al., [@B42]; He and Shen, [@B85]; Winner and Winkler, [@B221]). In mammals, one area where neuroblasts that give rise to adult-born neurons are generated is the subventricular zone (SVZ) (Lim and Alvarez-Buylla, [@B133]; Alvarez-Buylla et al., [@B3]; Kazanis, [@B103]; Ernst et al., [@B58]). In PD, a number of studies reported an impairment of the SVZ, where loss of the neurotransmitter dopamine, from mDA cell bodies innervating Type C cells in the SVZ, was causally related to the decreased neurogenic potential (Baker et al., [@B7]; Höglinger et al., [@B92], [@B91]; Freundlieb et al., [@B65]; Borta and Höglinger, [@B22]; O\'Keeffe et al., [@B159]; Lennington et al., [@B121]). In addition, certain dopamine agonist therapies were reported to rescue NSC proliferation in PD (O\'Keeffe et al., [@B159],[@B160]; Winner et al., [@B222]).

Notably, within the SVZ microenvironment (i.e., the "stem cell niche"), NSCs are in close contact with astroglial cells that modulate stem cell proliferation, migration and/or neuron differentiation, through the release of a panel of factors including morphogens, growth/neurotrophic factors and immunoregulatory molecules, thus implicating their active participation in NSC homeostatic regulation (Lim and Alvarez-Buylla, [@B133]; Alvarez-Buylla et al., [@B3]). Amongst others, Wnts are important modulators of adult neurogenesis, and *Wnt/*β*-catenin* is a vital pathway regulating self-renewal and differentiation of neural stem progenitor cells, NSCs (Adachi et al., [@B2]; Kalani et al., [@B101]; Kuwabara et al., [@B113]; Zhang L. et al., [@B229]; Shruster et al., [@B190]). Of special importance, inflammatory mechanisms both at the CNS and peripheral levels play an important role in the modulation of neurogenesis in the adult, aged and injured brain (Ekdahl et al., [@B55], [@B56]; Jakubs et al., [@B97]; Pluchino et al., [@B172]; Thored et al., [@B205]; Martino et al., [@B145]; Tepavcević et al., [@B203]; Villeda et al., [@B210]; Cusimano et al., [@B43]; Ekdhal, [@B57]; Kokaia et al., [@B109]; L\'Episcopo et al., [@B128]; Wallenquist et al., [@B213]; Wadhwa et al., [@B212]).

Hence, work in our laboratory focused on the potential for inflammation and astrocyte-microglia crosstalk to modulate the SVZ neurogenic niche, which is bordered by the corpus striatum. Here, NSC proliferative and neuron differentiation potential were monitored, both *in vivo* and *ex vivo*, as a function of aging and PD-induced morphological and functional changes of the striatal astroglial cell compartment. Additionally, we addressed the potential role of Wnt signaling in the neuroinflammatory regulation of SVZ neurogenesis. We thus uncovered that the Wnt/β-catenin signaling pathway is involved in the regulation of adult neurogenesis with advancing age and inflammation, and suggested crosstalk between inflammatory and *Wnt/*β*-catenin* signaling components (L\'Episcopo et al., [@B128]). *In vivo* experiments showed an inverse correlation between the SVZ-neurogenic impairment of MPTP mice with the M1 glial activation status in striatum, with a maximal NSC inhibition corresponding to greatest microglia activation, as evidenced by increased of striatal iNOS, TNF-α, and IL-1β expression both at a mRNA and protein levels (L\'Episcopo et al., [@B128], [@B129]). These effects were associated to a marked β-catenin downregulation in the SVZ, in face of up-regulated levels of active pGSK-3β, reduced NSC proliferation and neuron differentiation (L\'Episcopo et al., [@B128], [@B129]). The observed up-regulation of active *pGSK-3*β in the face of β*-catenin* depletion in SVZ after MPTP exposure shown *in vivo*, was further supported both in *ex vivo* and *in vitro* experiments, further implicating disruption of β*-catenin* signaling in SVZ-NSC of MPTP mice (L\'Episcopo et al., [@B128], [@B129]).

*In vitro* studies using different coculture systems between young/aged glia with young/aged NSCs, and in the absence or the presence of MPTP/MPP^+^, next indicated that young M2-microglia increased NSC neurogenic potential, but upon MPP^+^ exposure, microglia shifted to the activated M1 phenotype and released high levels of pro-inflammatory mediators, inhibiting NSC proliferation, neuron differentiation and β-catenin expression, thus underscoring crosstalk between inflammatory and *Wnt/*β*-catenin* signaling components (L\'Episcopo et al., [@B126], [@B128], [@B129]). Importantly, astrocyte-microglia crosstalk was also shown to determine a further level of glial regulation of NSC neurogenic potential, as young astrocytes exposed to aged microglia fail to express Wnt1 and were no longer capable to promote NSC proliferation (L\'Episcopo et al., [@B129]), suggesting that M1 phenotype sharply inhibits astrocyte proneurogenic capacities also via Wnt1 inhibition.

Interestingly, treatment with NO-flurbi of aged MPTP mice had the potential to rescue aging-induced SVZ impairment by a switch of the M1 harmful phenotype. This NO-flurbi-induced mitigation of the inflammatory SVZ microenvironment protected NSCs against mitochondrial impairment and cell death, and promoted proliferation and neurogenesis in the SVZ, which associated to a substantial striatal DA reinnervation both in young and aged mice MPTP mice, possibly resulting from NO-flurbi induced rescue of mDA neuronal cell bodies in the SN (L\'Episcopo et al., [@B129]).

We then looked at one key factor involved in the mechanism by which cells combat oxidative stress and inflammation, the Nrf2-pathway, recognized to participate to nigrostriatal neuroprotection (Chen et al., [@B31]). Interestingly, we found that the Nrf2-antioxidant system was markedly impaired in SVZ astrocytes of aging mice, as a result of disrupted microglia-astrocyte crosstalk. This impairment, in turn, resulted in a failure of SVZ to adapt to the changing oxidative and inflammatory milieu of the aged SVZ niche ("the first hit"). Next, exposure to the PD neurotoxin ("the second hit") in aging mice, further inhibited SVZ neurogenic potential (Figure [3](#F3){ref-type="fig"}). Interestingly, aged microglial inhibitory effects on NSCs proliferation and neuron formation was shown to rely on the *PI3K (phosphatidylinositol3-kinase)/Akt*-pathway, and with the intermediacy of the *Wnt/*β*-catenin* signaling cascade (L\'Episcopo et al., [@B129]). Hence modulating *PI3K/Akt* and the *Wnt/Fzd/*β*-catenin* signaling cascades, was capable to switch on or off the activation of *GSK-3*β in SVZ-NSCs. Notably, NO-flurbi induced reversal of aging-induced SVZ impairment also associated to normalization of these age-related changes in Nrf2 and Wnt/β-catenin pathways (Figure [3](#F3){ref-type="fig"}), and significantly counteracted MPTP neurotoxic effects at striatal and SN levels.

Together, reactive astrocytes and microglia play a prominent role in the remodeling of the SVZ niche of PD rodents. Interestingly, glia-NSC interactions are in part regulated by crosstalk between inflammatory and Wnt/β-catenin signaling cascades. While further studies are clearly needed to address the causal relationship between the reversal of SVZ impairment and nigrostriatal neurorepair in aged-MPTP mice, such inflammatory modulation of SVZ neurogenesis herein described appears of special interest in light of accumulating evidence documenting that mitigating the inflammatory status, improving the neuronal microenvironment, and promoting mitochondrial function all together may represent a window of opportunity for therapeutic strategies aimed at upregulating endogenous neurogenesis, to favor the integration or survival of new neurons, to incite neurorepair, and/or to ameliorate some cognitive functions (Ehninger et al., [@B54]; L\'Episcopo et al., [@B128], [@B131]; Rueger et al., [@B181]; Sakata et al., [@B182]; Vukovic et al., [@B211]; Wallenquist et al., [@B213]; Marchetti and Pluchino, [@B138]; Radad et al., [@B179]; Wadhwa et al., [@B212]; Yang et al., [@B224]).

Genetic mutations, inflammation and mDA neurodegeneration: mRNAs/miRNAs and Wnt signaling interplay {#s6}
===================================================================================================

Finally, the crucial link between inflammation and PD is further exemplified by the fact that key PD-associated genes, such as α-Syn (SNCA), PARK2, deglycase (DJ-1), leucine-rich repeat kinase 2 (LRRK2), and glucocerebrosidase (GBA) are all expressed in immune cells, suggesting their potential to modulate inflammation (Dzamko et al., [@B52]). Reciprocally, an increasing number of PD-related genes including LRRK2, VPS35, PINK1, UCHL-1, Parkin, ATP6AP2, and GBA modulate the canonical Wnt pathway (Berwick et al., [@B15] and Refs. therein), further underlinying a critical Wnt/inflammatory connection in PD (Marchetti and Pluchino, [@B138]).

In addition a synergy between the genetic background and exposure to various neurotoxic or inflammatory challenges is recognized to promote a self-perpetuating cycle of microglial-mediated mDA neurotoxicity (Zhang et al., [@B231]; Gao and Hong, [@B67], [@B69]; Marchetti et al., [@B140]; Gao et al., [@B70]; Lastres-Becker et al., [@B117]; Table [1](#T1){ref-type="table"}). Notably, such feedforward cycle of chronic activation of microglia and chronic damage of mDA neurons are likely to play a decisive role for the severity of nigrostriatal DA lesion and the overall detrimental effects of SNpc neurons and consequently, their capacity for neurorepair.

A number of laboratories showed the harmful consequences of dysfunctional α-Syn coupled to the M1 pro-inflammatory phenotype, capable to potentiate each other and promote the progression of mDA neuron death (Gao et al., [@B69]; Harms et al., [@B83]; Sanchez-Guajardo et al., [@B184]). Notably, Lastres-Becker et al. ([@B117]) reported that a dysfunctional anti-oxidant system in NRf2-deficient mice coupled to α-syn dysfunction in early-stage of PD can synergize together resulting in exacerbated inflammation, up-regulated protein aggregation, all together promoting increased neuronal death. Additionally, as reported by Frank-Cannon et al. ([@B64]), Parkin (the product of the *PARK2* gene) deficiency, increases the vulnerability of mDA neurons to various risk factors including inflammation-dependent degeneration. Another important connection is the one between LRRK2 mutation and the activation of M1 proinflammatory phenotype (Gillardon et al., [@B73]), acting in synergy to amplify mDA neurotoxicity. By contrast, when LRRK2 is inhibited, this in turn reduces the production of microglial harmful mediators and reverses mDA neurotoxicity (Kim et al., [@B105]; Moehle et al., [@B148]; Lee et al., [@B119]). Notably, a robust LRRK2 expression is present in immune cells, including peripheral monocytes and macrophages, and in primary microglia (Dzamko et al., [@B52]). Of interest, peripheral inflammation appears greater in a percentage of subjects carrying LRRK2-G2019S mutation, with the cytokine IL-1β discriminating asymptomatic LRRK2-G2019S carriers from controls (Dzamko et al., [@B53]). Furthermore, the expression of LRRK2 is modulated by immune cell-specific signals, like IFNγ and toll-like receptor (TLR) agonists (see Moehle et al., [@B148]) thereby reinforcing the LRRK2/immunological link.

Notably, LRRK2 binds three central Wnt signaling components (Sancho et al., [@B185]; Berwick and Harvey, [@B12]), while loss of LRRK2 and mutations of *LRRK2* are linked to Wnt signaling (Sancho et al., [@B185]; Berwick and Harvey, [@B12],[@B13], [@B14]; Berwick et al., [@B15]). Hence, pathogenic *PARK8* mutations impact upon the activity of the canonical Wnt pathway (Berwick and Harvey, [@B12]). Recent evidence indicates that in the context of canonical Wnt signaling, pathological LRRK2 mutations are gain-of function, enhancing the repression of β-catenin mediated by LRRK2, thus inhibitng *canonical* Wnt/β-catenin signaling (Berwick et al., [@B15]). Such connection between LRRK2 and Wnt cascades in PD support the growing body of studies highlighting dysregulated Wnt signaling in PD (see Harvey and Marchetti, [@B84] and chapters therein).

*PARK17* encodes the vacuolar protein sortin 35 homolog gene, VPS3, and its mutation is linked to autosomal dominant late-onset PD, with an involvement in iron up-take and Wnt/β-catenin signaling (Deng et al., [@B47]). Of note iron together with other risk factors, such as exposure to paraquat, may interact to aggravate neuroinflammation and age-dependent mDA neuron death (Peng et al., [@B166]).

Further compelling evidences from the last few years implicate certain miRNAs in the counter-regulation of microglia M1 phenotype associated to robust activation (Table [2](#T2){ref-type="table"}). For example the group of Prajapati in 2015 found that TNF-α was able to both trigger cell death and sensitize to apoptosis the DA cell line SH-SY5Y, in the presence of different PD neurotoxins---such as MPP+, 6-OHDA and Rotenone---via miRNA deregulation (Prajapati et al., [@B176]). Following the treatment with TNF-α, 9 miRNAs were found upregulated (let-7b, let-7g, miR-103, miR-155, miR-16-5p, miR-17, miR-204, miR-27, and miR-98) and 7 downregulated (let-7a, miR-128, miR-145, miR-181a, miR23a, miR-23b, and miR-320a). Interestingly, the upregulated miRNAs were predicted to target mRNAs involved in both neuronal-specific pathways (i.e., neuronal differentiation, axonal guidance and nerve projection development) and mitochondrial respiratory subunits. In particular, the authors demonstrated that, in the presence of TNF-α, both miR-155 and miR-27 were able to downregulate ATP5G3, a subunit of F1-ATP synthase. This study strongly supports the role of TNF-α as a critical regulator of miRNAs targeting mitochondrial functions, which in turn may cause DA neuronal loss (L\'Episcopo et al., [@B125],[@B124], [@B127]; Prajapati et al., [@B176]).

###### 

M1 pro-inflammatory phenotype and miRNA dysregulation in PD.

  **miRNAs**                                                                     **Expression levels**   **Outcomes**                                                                                                    **References**                                                                                                                                                      
  ------------------------------------------------------------------------------ ----------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  let-7b, let-7g, miR-103, miR-155, miR-16-5p, miR-17, miR-204, miR-27, miR-98   ↑                       **Upregulation** following TNF-α treatment in SH-SY5Y cells                                                                                                                                                                                                                         Prajapati et al., [@B176]
  let-7a, miR-128, miR-145, miR-181a, miR23a, miR-23b, miR-320°                  ↓                       **Downregulation** following TNF-α treatment in SH-SY5Y cells                                                                                                                                                                                                                       
  miR-155, miR-27                                                                ↑                       **Upregulation** following TNF-α treatment in SH-SY5Y cells                                                     ATP5G3 (F1-ATP synthase subunit) downregulation in mitochondria of SH-SY5Y cells                                                                                    
  miR-155                                                                        ↓                       **Downregulation** following *antago-miR-155* administration in TNF-α-treated SH-SY5Y cells                     Increased SH-SY5Y cells survival following TNF-α treatment                                                                                                          
  miR-155                                                                        ↑                       **Upregulation** following LPS, IFN-γ or TNF-α treatments in THP-1 cells                                        Downregulation of FADD, SOC1, IKK, IL13Rα1 and SMAD2                                                                                                                Louafi et al., [@B135]; Liu and Abraham, [@B134]; Ponomarev et al., [@B173]; Yang et al., [@B225]
                                                                                 ↓                       **Downregulation** following *antago-miR-155* administration in atherosclerosis mouse model                     Downregulation of TNF-α, IL-1β, CCL2, CCL4, and CCL7 secretion in serum and vascular tissues                                                                        Yang et al., [@B225]
                                                                                 ↑                       **Upregulation** in PD mice overexpressing α-SYN                                                                Inflammatory response to α-SYN fibrils and reactive microgliosis                                                                                                    Thome et al., [@B204]
  miR-7                                                                          ↓                       **Downregulation** in neurons of MPTP-treated mice                                                              α-SYN upregulation                                                                                                                                                  Junn et al., [@B100]; Zhou et al., [@B232]
                                                                                 ↑                       **Upregulation** following *miR-7 mimic* injection in MPTP-treated mice                                         Downregulation of α-SYN and downregulation of NRLP3 in DA neurons with suppression of inflammasome-mediated neuroinflammation and attenuated DA neurodegeneration   
                                                                                 ↓                       **Downregulation** following *antago-miR-7* administration in MSU or ATP treated BV2 cells                      Upregulation of NLRP3 expression and aggravated inflammasome activation *in vitro*                                                                                  
  miR-135b                                                                       ↓                       **Downregulation** in MPP+-treated SH-SY5Y cells                                                                GSK3β upregulation[^**§**^](#TN5){ref-type="table-fn"}                                                                                                              Wang et al., [@B215]; L\'Episcopo et al., [@B126],[@B123]; Zhang et al., [@B228]
                                                                                 ↑                       **Upregulation** following *miR-135b mimic* administration in SH-SY5Y cells                                     GSK3β downregulation, TNF-α and IL-1β reduction, MPP+-induced apoptosis rescue[^**§**^](#TN5){ref-type="table-fn"}                                                  
  miR-7116-5p                                                                    ↓                       **Downregulation** in microglia of MPTP-treated mice                                                            miR-7116-5p directly targets and inhibits TNF-α expression. In MPTP mice miR-7116-5p is downregulated, consequently TNF-α production is boosted                     He et al., [@B86]
                                                                                 ↑                       **Upregulation** following *lentiviral-mediated miR-7116-5b overexpression* in microglia of MPTP-treated mice   Downregulation of TNF-α, reduction of TNF-α-mediated inflammatory activation and prevention of DAergic neuronal loss                                                

*Wnt/β-Catenin dysregulation in the reported conditions*.

Notably, miR-155 was previously shown to be involved in the regulation of inflammatory processes. The induction of miR-155 (via LPS, IFN-γ, and TNF-α) is able to target key regulators of inflammation, such as FADD, SOC1, IKK, IL13Rα1, and SMAD2, while miR-155 inhibition results in the upregulation of the proinflammatory molecules IL-1β, IL-6, TNF-α, and iNOS (Louafi et al., [@B135]; Liu and Abraham, [@B134]; Ponomarev et al., [@B173]; Yang et al., [@B225]).

The relevance of miR-155 in PD was confirmed in 2016 by Thome and colleagues that observed miR-155 upregulation in a PD mouse model overexpressing α-SYN. They demonstrated that miR-155 is crucial to mediate the inflammatory response to α-SYN fibrils, responsible of reactive microgliosis and accounting for the loss of DA neurons, triggered by the overexpression of α-SYN (Thome et al., [@B204]).

Other miRNAs are recently emerging as important regulators of M1 microglial pro-inflammatory phenotype, such as miR-7, previously reported to target α-SYN in DA neurons (Junn et al., [@B100]). In 2016 miR-7 was demonstrated to directly target microglial nod-like receptor protein 3 gene (NRLP3), suppressing inflammasome-mediated neuroinflammation and thus suggesting a potential therapeutic role of this miRNAs in the context of PD (Zhou et al., [@B232]).

There are also interesting clues linking Wnt/β-catenin pathway to miRNA-modulation of DA neuronal survival and inflammation (Table [2](#T2){ref-type="table"}). In fact, the role of miR-135b as GSK3β regulator was recently investigated in MPP^+^-treated SH-SY5Y cells (Zhang et al., [@B228]). The specific pharmacological inhibition of GSK3β reversed MPTP-induced neuron injury and also improves MPTP-induced behavioral impairment (Wang et al., [@B215]; L\'Episcopo et al., [@B126],[@B123]). Interestingly, miR-135b was reduced in face of GSK3β upregulation in MPP^+^-treated cells, in a dose- and a time-dependent manner. Importantly, the overexpression of miR-135b was able to directly target GSK3β, and to reduce the levels of pro-inflammatory cytokines TNF-α and IL-1β, thus rescuing the MPP^+^-induced apoptosis (Zhang et al., [@B228]).

The same year, also miR-7116-5p was suggested to be a key player in neuroinflammation. Specifically in microglia of an MPTP mouse model, miR-7116-5p was found to be downregulated, while TNF-α increased. This miRNA was demonstrated to directly target TNF-α transcript, thus reducing TNF-α-mediated inflammatory activation and finally preventing DAergic neuronal loss in MPTP mice (He et al., [@B86]).

Together, gene-environment interactions crucially impact in switching microglia status to the M1 neuron destructive phenotype, with the contribution of both mRNAs and miRNAs, and Wnt/β-catenin signaling interplay.

Concluding remarks and future perspectives {#s7}
==========================================

In this work we have highlighted the evidences documenting a major role of gene-environment interactions directing the polarization of microglia toward an harmful M1 phenotype, that may predispose the brain to reach a critical threshold of inflammation, triggering a self-perpetuating cycle of inflammation and neuronal death. Especially, we pinpointed the role of Wnt signaling in each of the steps involved in both the neuroprotective/destructive glial-mediated neuronal outcome in PD.

Aging is a critical period for the vulnerability to PD. Importantly, aging reduces the degree of DAergic neuron plasticity, diminishes mDA neuron adaptive capacity, exacerbates inflammation and impair neurogenesis, at least in part via a dysfunction Wnt/β-catenin signaling and the crosstalk with inflammatory pathways. The inflammatory involvement in the regulation of adult neurogenesis suggest that harnessing inflammatory responses through targeted modulation of innate immunity during the pre-motor phase of PD may have potential therapeutic implications to incite endogenous neurogenesis and neurorepair in PD. Finally, aging, inflammation and major genetic mutations, together with a set of recently uncovered inflammation-dependent miRNA, all together impact on Wnt/β-catenin signaling pathway, with potential consequences for PD degeneration.

All together, unraveling the complex molecular circuity linking key molecular genetic and environmental drivers in PD with microglia polarization will permit to identify new drugable targets for the cure of PD.
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